RBC Capital analyst Ben Hendrix raised the firm’s price target on Elevance Health to $523 from $505 and keeps a Sector Perform rating on the shares. The company’s Q4 results were "solid" and finished the year just ahead of its long-term earnings growth target of 12%-15%, the analyst tells investors in a research note. Elevance Health has good momentum into an optimization year, supported by stronger pricing in both the commercial and government books, but a neutral stance reflects its "shifting membership" driven by pricing measures and redetermination uncertainty, RBC Capital states.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ELV:
- Early notable gainers among liquid option names on January 25th
- Elevance Health raises share repurchase program by $5B
- Elevance Health raises quarterly dividend 16% to $1.48 per share
- Elevance Health reports Q4 adjusted EPS $5.23, consensus $5.19
- Elevance Health to acquire Blue Cross and Blue Shield of Louisiana